
DBV Technologies S.A. DBVT
$ 21.71
0.46%
Quarterly report 2025-Q2
added 07-29-2025
DBV Technologies S.A. Total Current Liabilities 2011-2026 | DBVT
Annual Total Current Liabilities DBV Technologies S.A.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 31.1 M | 37.3 M | 29.5 M | 31.4 M | 52.7 M | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 52.7 M | 29.5 M | 36.4 M |
Total Current Liabilities of other stocks in the Biotechnology industry
| Issuer | Total Current Liabilities | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
ARCA biopharma
ABIO
|
13 M | - | 1052.0 % | $ 415 M | ||
|
Adaptive Biotechnologies Corporation
ADPT
|
98.1 M | $ 18.24 | -1.41 % | $ 2.68 B | ||
|
Amgen
AMGN
|
23.1 B | $ 344.45 | 0.75 % | $ 185 B | ||
|
Arrowhead Pharmaceuticals
ARWR
|
195 M | $ 73.14 | 5.5 % | $ 9.78 B | ||
|
I-Mab
IMAB
|
576 M | - | - | $ 866 M | ||
|
Biogen
BIIB
|
5.53 B | $ 178.43 | -0.81 % | $ 26 B | ||
|
Aytu BioScience
AYTU
|
63.1 M | $ 2.7 | 3.85 % | $ 17 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
1.62 B | - | - | $ 40.3 B | ||
|
Adagene
ADAG
|
38.2 M | $ 2.87 | 4.36 % | $ 162 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
1.77 M | - | -1.52 % | $ 24.7 M | ||
|
Akero Therapeutics
AKRO
|
39.8 M | - | - | $ 3.67 B | ||
|
Acorda Therapeutics
ACOR
|
228 M | - | -24.86 % | $ 820 K | ||
|
Aptose Biosciences
APTO
|
4.46 M | - | -45.71 % | $ 1.2 M | ||
|
Acasti Pharma
ACST
|
1.93 M | - | 4.01 % | $ 150 M | ||
|
Aeglea BioTherapeutics
AGLE
|
54.1 M | - | - | $ 1.01 B | ||
|
Akebia Therapeutics
AKBA
|
99.9 M | $ 1.39 | -1.42 % | $ 261 M | ||
|
Albireo Pharma
ALBO
|
45.3 M | - | -0.23 % | $ 916 M | ||
|
Институт стволовых клеток человека
ISKJ
|
556 M | - | - | - | ||
|
Allena Pharmaceuticals
ALNA
|
15.7 M | - | 3.16 % | $ 1.9 M | ||
|
Ampio Pharmaceuticals
AMPE
|
2.38 M | - | -11.43 % | $ 502 K | ||
|
Applied Molecular Transport
AMTI
|
15.1 M | - | - | $ 10.1 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
2.05 M | $ 4.12 | 2.74 % | $ 8.96 B | ||
|
Aravive
ARAV
|
22.1 M | - | -13.39 % | $ 1.45 M | ||
|
Athira Pharma
ATHA
|
13.1 M | - | - | $ 269 M | ||
|
Autolus Therapeutics plc
AUTL
|
60.7 M | $ 1.39 | 1.09 % | $ 355 M | ||
|
AgeX Therapeutics
AGE
|
5.91 M | - | -10.17 % | $ 12.2 K | ||
|
AVROBIO
AVRO
|
6.35 M | - | 1083.1 % | $ 745 M | ||
|
Cardiff Oncology
CRDF
|
13.4 M | $ 1.75 | -0.29 % | $ 83.4 M | ||
|
Akouos
AKUS
|
16.8 M | - | 0.23 % | $ 488 M | ||
|
Compugen Ltd.
CGEN
|
20.2 M | $ 1.85 | 0.54 % | $ 166 M | ||
|
Adaptimmune Therapeutics plc
ADAP
|
72.8 M | - | -15.15 % | $ 60.3 M | ||
|
Brickell Biotech
BBI
|
1.66 M | - | -5.38 % | $ 6.06 M | ||
|
Amneal Pharmaceuticals
AMRX
|
1.13 B | $ 14.11 | 3.14 % | $ 4.36 B | ||
|
AIkido Pharma
AIKI
|
3.78 M | - | 1.93 % | $ 17.4 M | ||
|
Atreca
BCEL
|
16.3 M | - | -11.76 % | $ 5.79 M | ||
|
Acer Therapeutics
ACER
|
19 M | - | 2.71 % | $ 14 M | ||
|
BioCryst Pharmaceuticals
BCRX
|
160 M | $ 6.64 | 0.91 % | $ 1.37 B | ||
|
Alpine Immune Sciences
ALPN
|
58 M | - | - | $ 2.17 B | ||
|
AlloVir
ALVR
|
5.24 M | - | 4.14 % | $ 49.1 M | ||
|
Beam Therapeutics
BEAM
|
182 M | $ 27.95 | 1.19 % | $ 2.3 B | ||
|
BeiGene, Ltd.
BGNE
|
2.21 B | - | 0.49 % | $ 251 B |